They may have to turn to scumbags’
MARCUS Davies believes last week s court decision will only act to push MS sufferers into the murky world of drug dealers. Instead of giving a donation of £5 for pain-relieving chocolate bars, Mr Davies told The Hunts Post that MS sufferers would have to
MARCUS Davies believes last week's court decision will only act to push MS sufferers into the murky world of drug dealers.
Instead of giving a donation of £5 for pain-relieving chocolate bars, Mr Davies told The Hunts Post that MS sufferers would have to "pay £25 to drug-dealing scumbags"
He said: "I'm ever so proud to have helped so many people, but these people are now in great jeopardy."
Mr Davies said the business, THC4MS (Therapeutic Help from Cannabis for Multiple Sclerosis) never paid for the cannabis it supplied. It was given to them by UK growers.
"We never actually bought cannabis from the illegal market. (Our suppliers) are good, honest people who know that this is the best medicine in the world."
He added: "In our mission statement, it says the supply of cannabis chocolate bars will continue until there was a viable alternative.
Most Read
- 1 Police searching for missing man discover body
- 2 Jail for man who boasted he was the St Ives 'weed man'
- 3 Huntingdon and Peterborough hospitals bring back masks after rise in Covid numbers
- 4 Car rolled in crash on A14
- 5 John Major's 'bad luck' comment is 'absolutely disgraceful' says son of victim
- 6 Woman has 'medical episode' during A1(M) crash
- 7 Two-day closure set for B661 between Great Staughton and Grafham Water
- 8 Outdoor inflatable water park returns to Huntingdonshire
- 9 Thousands come together at RAF Wyton for Armed Forces Day
- 10 Garden railway raises money for 3 Pillars
"That has happened, there is now Sative, a natural product with plant extracts that costs £100 a bottle."
Mr Davies said the bottle contains 52 doses but only lasts two weeks once opened. This means a cost of £200 a month - a price the NHS cannot afford.
He said treatment had been trialled in Europe where the manufacturers, GW Pharmaceuticals, were hoping to get a licence.
Mr Davies, who said he is a shareholder in the company, added: "It was cleared for use in the UK in November 2005 but primary care trusts decided that the drug was too expensive.
